CRISPR-Cas9 targeting of MMP13 in human chondrocytes leads to significantly reduced levels of the metalloproteinase and enhanced type II collagen accumulation - Seidl, CI; Fulga, TA; Murphy, CL (Osteoarthritis Cartilage, 2019)